A randomized controlled study of autogenous platelet-rich gel and standard therapy in the treatment of diabetic refractory skin ulcer

1Mohammed J. Alfeehan, Luay Asaad Mahmood, Salah Ismael Abdulelah

173 Views
59 Downloads
Abstract:

Objective To evaluate the efficacy and safety of autogenous platelet-rich gel (APG) in the treatment of diabetic refractory skin ulcers. Methods from April 2017 to February 2018, 56 patients with diabetic skin ulcers hospitalized in our department were randomly divided into APG treatment (23 cases) and standard treatment group (33 cases). Both groups of patients used insulin to control blood sugar, strictly control the orbit and blood lipids, and were given anti-blood plates, improved microcirculation, anti-infection and other general treatments and standard treatment of local ulcer wounds. Patients in the APG treatment group used self-made APG and applied wound dressing according to the wound volume / area; the standard treatment group applied wound dressing directly. The course of treatment is until the wound is healed, a flap transplant is performed, or it is over 12 weeks. Results All patients except the standard treatment group were lost to follow-up. The ulcer healing rate in the APG group was 22/23 (95.7%) and the total effective rate was 100%; the ulcer healing rate in the standard treatment group was 23/33 (69.6%) and the total effective rate was 72.1% The difference between the two groups was statistically significant (P values ​​were o.002 and O.009, respectively); analysis of the healing curve and sinus closure curve during Meier ulcer in Kaplan Meier analysis P <O. 05, showing that APG treatment was significantly better than standard treatment; no side effects related to APG treatment were found during treatment. Conclusion APG is better than standard treatment for diabetic refractory skin ulcers, and it has more advantages in treating ulcers with sinus tract; APG is safe, effective and feasible for diabetic refractory skin ulcers.

Keywords:

autogenous platelet-rich gel, randomized controlled trial, diabetic foot, refractory skin ulcer.

Paper Details
Month6
Year2020
Volume24
IssueIssue 1
Pages5136-5140